Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Catherine M Lanagan"'
Autor:
Michelle A Neller, Michael H-L Lai, Catherine M Lanagan, Linda E O'Connor, Antonia L Pritchard, Nathan R Martinez, Christopher W Schmidt
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e110741 (2014)
While cloned T cells are valuable tools for the exploration of immune responses against viruses and tumours, current cloning methods do not allow inferences to be made about the function and phenotype of a clone's in vivo precursor, nor can precise c
Externí odkaz:
https://doaj.org/article/d11adaf970244ecea3c97633192bcdc9
Autor:
Catherine M. Lanagan, Judith Symmons, Adrian C. Herington, Nicholas K. Hayward, Vanessa F. Bonazzi, Mitchell S. Stark, Jane M. Palmer, Glen M. Boyle, Christopher W. Schmidt, Pamela M. Pollock, Robert Ballotti
Publikováno v:
Oncotarget
EBioMedicine
ResearcherID
EBioMedicine
ResearcherID
// Mitchell S. Stark 1,2 , Vanessa F. Bonazzi 3 , Glen M. Boyle 1 , Jane M. Palmer 1 , Judith Symmons 1 , Catherine M. Lanagan 1 , Christopher W. Schmidt 1 , Adrian C. Herington 2 , Robert Ballotti 3 , Pamela M. Pollock 2 and Nicholas K. Hayward 1 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c42d9cbb50b48c6c36d84ccf3934f71f
https://doi.org/10.18632/oncotarget.3924
https://doi.org/10.18632/oncotarget.3924
Autor:
Gregory J. Slater, Kay A.O. Ellem, José A. López, David Thomas, Nathan R. Martinez, Christopher W. Schmidt, Maree K. Johnson, Catherine M. Lanagan, Janet L. See, Linda O'Connor, Michael G. E. O'Rourke
Publikováno v:
Melanoma Research. 17:316-322
Active boosting of the antitumour immune response of patients with solid malignancies has been tested in a large number of trials. Isolated complete clinical responses have been reported, however, they have not been replicated in subsequent studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9b2ab4c6012ab2ff3b2558aec3f3f7
https://doi.org/10.1097/cmr.0b013e3282c3a73b
https://doi.org/10.1097/cmr.0b013e3282c3a73b
Autor:
Trevor H. Forster, Maree K. Johnson, Nathan R. Martinez, Christopher W. Schmidt, J. Alejandro Lopez, Julia A Marshall, Michael G. E. O'Rourke, Janet L. See, Linda O'Connor, Kay A.O. Ellem, Catherine M. Lanagan, David M. Purdie
Publikováno v:
Immunology & Cell Biology. 84:295-302
Current treatment options for advanced metastatic melanoma are limited to experimental regimen that provide poor survival outcomes. Immunotherapy is a promising alternative and we recently reported a clinical trial in which 6 out of 19 patients enrol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e577d70e4614b2d86f4ffb4572605ade
https://doi.org/10.1111/j.1440-1711.2006.01445.x
https://doi.org/10.1111/j.1440-1711.2006.01445.x
Autor:
Catherine M. Lanagan, Linda E. O′Connor, Antonia L. Pritchard, Michelle A Neller, Michael H.-L. Lai, Nathan R. Martinez, Christopher W. Schmidt
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 11, p e110741 (2014)
PLoS ONE, Vol 9, Iss 11, p e110741 (2014)
While cloned T cells are valuable tools for the exploration of immune responses against viruses and tumours, current cloning methods do not allow inferences to be made about the function and phenotype of a clone's in vivo precursor, nor can precise c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f815b5cd26c2342ffd589835cf7316fa
http://europepmc.org/articles/PMC4219695
http://europepmc.org/articles/PMC4219695
Autor:
Donald Chow, Susan L. Woods, Natalie M. Niemi, Victoria Zismann, Jeffrey P. MacKeigan, Jonathan Ellis, Yuanqing Wu, Lauren G. Aoude, Richard A. Gibbs, Irene Newsham, Catherine M. Lanagan, Ken Dutton-Regester, Christopher W. Schmidt, Kevin M. Brown, Donna M. Muzny, Michael Gartside, Chris Sereduk, David Youngkin, Bradford R. Brooks, Mitchell S. Stark, Jeffrey M. Trent, Nanyun Tang, Hongwei Yin, Jeffrey S. Reid, Thomas Pollak, Nicholas K. Hayward, Vanessa F. Bonazzi, Sonika Tyagi, Bostjan Kobe, Jane M. Palmer
Publikováno v:
Nature genetics
We sequenced eight melanoma exomes to identify new somatic mutations in metastatic melanoma. Focusing on the mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) family, we found that 24% of melanoma cell lines have mutations in the protein-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d41db2fa74dbb2fc476205abb32c039
https://pubmed.ncbi.nlm.nih.gov/22197930
https://pubmed.ncbi.nlm.nih.gov/22197930
Autor:
Beverley Mavis Kerr, Catherine M. Lanagan, Suzanne L. Elliott, Christopher W. Schmidt, John R. Bell, Beth Crowe, Greg J. Slater, Kay A.O. Ellem, David M. Purdie, Michael G. E. O'Rourke, Janet L. See, Maree K. Johnson, Jie Yang
Publikováno v:
Cancer immunology, immunotherapy : CII. 52(6)
Advanced metastatic melanoma is incurable by standard treatments, but occasionally responds to immunotherapy. Recent trials using dendritic cells (DC) as a cellular adjuvant have concentrated on defined peptides as the source of antigens, and rely on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b17ed359487b8799c98df3da6a0d64
https://pubmed.ncbi.nlm.nih.gov/12682787
https://pubmed.ncbi.nlm.nih.gov/12682787